Navigation Links
Glazer receives grant to study light-activated cancer drugs
Date:1/31/2013

LEXINGTON, Ky. (Jan. 31, 2013) University of Kentucky assistant professor of chemistry Edith "Phoebe" Glazer has received an American Cancer Society Research Scholar Grant for $715,000 over four years to continue her research into ruthenium-based cancer drugs. These compounds are less toxic to healthy cells than a similar and widely used inorganic drug.

Cisplatin is a common platinum-based cancer drug used in a variety of cancer treatments. But while cisplatin kills cancer cells, it also attacks healthy cells, causing debilitating side effects. Ruthenium is another transition metal and belongs to the same group of the periodic table as iron.

Previously, the Glazer group developed two new ruthenium complexes designed to kill cancer cells while preserving healthy cells. These complexes are inert in the dark, but when activated with light, they become up to 200 times as toxic, and up to three times as potent as cisplatin against tumor cells.

Funded by the American Cancer Society, the new grant will allow Glazer's team to develop improved ruthenium-based compounds and to study their effectiveness. Using the strategy of combining organic ligands as building blocks that assemble around the ruthenium center "core," a large family of compounds with different structures and properties can be rapidly synthesized. This is in marked contrast to approaches using compounds discovered in nature, called natural products, as chemotherapeutics.

Many chemotherapeutics are natural products, but their synthesis is challenging and there are limited chemical modifications that can be made into the molecules. In the ruthenium compounds, the organic components can be easily changed to alter chemical properties and possibly even what types of cells the compounds will enter in the body. The different structures can also potentially prevent the development of drug resistance, as tumors that become resistant to one particular ruthenium drug structure co
'/>"/>

Contact: Allison Perry
allison.perry@uky.edu
859-323-2399
University of Kentucky
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Loyola Cancer Center receives Outstanding Achievement Award
2. MU receives national award for using mind-body approach to improve health
3. Neuropsychologist receives University of Houstons highest faculty honor
4. Boston researcher, surgical oncologist receives national award
5. LA BioMed receives Grand Challenges Explorations grant
6. Lawson researcher receives 1 of first-ever Pfizer Psychiatry Research Awards
7. Dr. Arthur Slutsky, vice-president of research at St. Michaels, receives lifetime award
8. UC San Diego Superfund Research Program receives $15 million grant renewal
9. Markey receives $6.25 million to study deadly blood and bone marrow disease
10. Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis
11. UC Santa Barbaras Kavli Institute receives 2 grants to explore interface of physics and biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014. Kessler Foundation researchers have published a study ... the executive deficits found in individuals with multiple ... for executive deficits in multiple sclerosis? Evidence from ... ahead of print on August 18 by ... Victoria Leavitt, PhD, of the Manhattan Memory Center, ...
(Date:9/16/2014)... prospective study that compared patient-reported outcomes of a ... demonstrates that single fraction radiation therapy (SFRT) is ... (MFRT) when pain, function and quality of life ... the American Society for Radiation Oncology,s (ASTRO,s) 56th ... in patients, pain, function and degree of distress ...
(Date:9/16/2014)... presented at the ESMO 2014 Congress will be published ... to give you a first glimpse of what you ... the leading theme Precision Medicine in Cancer Care. , ... is now possible for an increasing number of cancers. ... a common goal --improved patient outcomes. This is the ...
(Date:9/16/2014)... 2014 The Pain Center of ... Ranking Arizona magazine, has selected Analance ™, ... , With TPC seeing hundreds of thousands of ... that was managed through “home grown” systems trying to ... clinical leadership teams. “Our current tools were not ...
(Date:9/16/2014)... September 16, 2014 Transparency Market Research, ... the global facial care market is expected to report ... report, titled ‘Facial Care Market (By Product Type - ... Cleansing Wipes, Serums and Masks and Others (fade creams, ... Growth, Trends and Forecast 2013 – 2019,’ is now ...
Breaking Medicine News(10 mins):Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:ESMO 2014 Congress Preview 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 3Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 2Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 3
... Masimo (Nasdaq: MASI ),the inventor of Pulse ... today that the Pricing Committee of its Board of,Directors ... plan is designed to enhance the Board,s ability to ... company,that do not offer an adequate price to all ...
... AKL, MONTREAL, Nov. 9 /PRNewswire-FirstCall/ - Akela ... on developing therapies for the,inhalation and pain markets, ... accounting principles for the three and six,month period ... consolidated net loss for the third quarter of ...
... on what footwear works best , , FRIDAY, Nov. 9 (HealthDay ... flip-flops and flexible walking shoes than with other types ... to barefoot, the better for the knees, the study finds. ... not only affects your feet but can affect other joints ...
... Stryker Corporation,(NYSE: SYK ) announced today that ... revised from the previous announcement dated,November 1, 2007. ... Piper Jaffray Health Care Conference New York, ... presentation will be available,on Stryker,s website at http://www.stryker.com ...
... 9 Give an Hour, a,non-partisan, non-profit organization offering ... ones, announces there are 750,providers nationwide on its network., ... network 10 percent, or 40,000,people, of the approximately 400,000 ... average fee of $100 an hour, this would save,the ...
... only realistic way of preventing deaths and severe complications ... the disease, concludes research published ahead of print in ... healthcare workers and others likely to be at risk ... immunised in the UK. But vaccination programmes for children ...
Cached Medicine News:Health News:Masimo Corporation Adopts Stockholder Rights Plan 2Health News:Masimo Corporation Adopts Stockholder Rights Plan 3Health News:Akela Pharma reports results for third quarter of fiscal 2007 2Health News:Akela Pharma reports results for third quarter of fiscal 2007 3Health News:Akela Pharma reports results for third quarter of fiscal 2007 4Health News:Close to Barefoot Best for Arthritic Knees 2Health News:Close to Barefoot Best for Arthritic Knees 3Health News:Close to Barefoot Best for Arthritic Knees 4Health News:Stryker to Present at Investor Conference 2Health News:Non-Profit Calls on Mental Health Professionals to Honor Veterans Day by 'Giving an Hour' of Free Counseling to Returning Veterans 2Health News:Chicken pox vaccination should be introduced for children in the UK 2
(Date:9/16/2014)... , Sept. 16, 2014 On September 25 ... exhibition focusing on medical design and manufacturing - MEDTEC ... Shanghai World Expo Exhibition & Convention Center, bringing together ... and regions to showcase their latest medical-grade raw materials, ... only one week remaining for free visitor pre-registration to ...
(Date:9/16/2014)... , Sept. 16, 2014 The Lupus ... LLY ) today released results from UNVEIL: ... sheds light on the lupus journey and the challenges ... for lupus caregivers. The UNVEIL study, which involved over ... devastating impact lupus has on all aspects of life ...
(Date:9/16/2014)... Sept. 16, 2014  DNAtrix, Inc., experts in ... patient was treated with the company,s lead product, ... in a randomized, multicenter, open-label Phase Ib study ... in collaboration with leading neurosurgeons and neuro-oncologists in ... of our randomized Phase Ib study of DNX-2401 ...
Breaking Medicine Technology:MEDTEC China 2014: Seven Highlights Not to Miss! 2MEDTEC China 2014: Seven Highlights Not to Miss! 3MEDTEC China 2014: Seven Highlights Not to Miss! 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2
... 3 out of 4 Patients in Cohort 2 Demonstrate T-Cell ... Potential ... Biopharmaceuticals,Corporation (TSX: NVN) today announced interim immunological data from the,first ... its lead product,candidate, HspE7, in patients with cervical intraepithelial neoplasia, ...
... 25, Astellas Pharma US, Inc. and its co-development,partner ... COM) announced the first,pivotal Phase III study evaluating ... today in Circulation,the official journal of the American ... the Atrial arrhythmia Conversion Trial (ACT I),the primary ...
Cached Medicine Technology:Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 3Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 4Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 5Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 6Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm 2Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm 3Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm 4Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm 5
... Rapidlab 800 System is a fully automated, ... care whole blood parameters in addition to ... allows the basic blood gas model to ... electrolytes, metabolites and CO-oximetry in a single ...
Microcomputer controlled, preparative ultracentrifuge, with CFC-free refrigeration system. Available either internally cooled or with external water cooling. Quikset user interface, Softspin automati...
... Sorvall DiscoveryTMM150 SE Micro-ultra centrifuge continues ... volume sample processing, now with 1,048,000 x ... bucket rotor. DiscoveryTMM150SE processes sample sizes ... a small floor footprint, brushless direct drive, ...
... and environmental safety are the ... K Ultracentrifuge from Beckman Coulter. ... centrifugation technology, the LE-80 K ... provide advanced capability for your ...
Medicine Products: